

Clinical Metal Toxicology

Tenth edition

2010

By Peter J. VanDerSchaar MD, PhD

Contributors to this book are:

Eleonore Blaurock-Busch, PhD

Lillian Ko, MD

Raymond Pahlplatz, MD

Hasnain Patel, MD

W.W. VanDerSchaar, PhD and K. Dam, MD

International Board of Clinical Metal Toxicology
IBCMT Head Quarters
Renheide 2
Leende 5595XJ, The Netherlands

For comments and enquiries:

IBCMT secretariat, attn Grace Claus gclaus@socal.rr.com

Editor: Slawomir Kubiak

Tenth edition: 2010

Copyright © September 2005

All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, recording or any information storage and retrieval system, without permission in writing from the authors.

...damnat quod non intelligit...

1 CONTENTS

1 CONTENTS	5
2 PREFACE	27
3 WHAT IS A METAL AND WHY CAN IT BE TOXIC?	29
3-1 Periodic Table of the Elements.....	29
3-2 Classification.....	30
3-2.1 Groups.....	30
3-3 Toxicity.....	31
3-3.1 Environmental metals.....	31
3-3.2 Mechanisms of toxicity.....	32
3-3.2.1 Mimicry.....	32
3-3.2.2 Oxidative damage.....	32
3-3.2.3 Protein adducts in biological systems.....	32
3-3.3 Exposure.....	32
3-3.3.1 Markers of Exposure.....	33
3-3.3.2 Adaptation.....	33
3-3.4 Sequestration, inclusion bodies.....	33
3-3.5 Metal transport by proteins.....	33
3-3.5.1 Specific metal-binding proteins.....	34
3-4 Metals in treatment of disease.....	34
3-5 Definitions.....	34
4 HISTORY OF CHELATING AGENTS	39
4-1 Ancient use of toxic metals.....	39
4-2 The use of toxic metals with the purpose of poisoning human adversaries.....	40
4-3 EDTA.....	42
4-3.1 First clinical application.....	42
4-3.2 EDTA and calcium.....	42
4-3.3 Clinical acceptance of EDTA.....	42
4-3.4 The structured denial of EDTA.....	43
4-3.5 The first symposia on EDTA chelation therapy.....	44
4-3.6 Other developments in EDTA chelation therapy.....	44
4-4 Organizations.....	44
4-5 Attacks.....	45
4-6 The Netherlands.....	45
4-7 Present situation with regard to EDTA.....	46
4-8 IBCMT.....	46
5 A CHEMISTRY REFRESHER	49
5-1 Reactive oxygen species (ROS).....	53
5-1.1 How reactive oxygen species are formed.....	54
5-1.2 Types of reactive oxygen species.....	55
5-1.2.1 Superoxide anion radical (O_2^-).....	55
5-1.2.2 Hydrogen peroxide (H_2O_2).....	55
5-1.2.3 Hydroxyl radical ($\cdot\text{OH}$).....	55
5-1.3 Inorganic and Organic.....	56
5-1.3.1 Nitric oxide (NO).....	57
5-1.3.2 Singlet oxygen ($^1\text{O}_2$).....	57
5-1.3.3 Ozone (O_3).....	57
5-2 Radiation.....	58
5-2.1 Units used in radiation measurements.....	58
5-2.1.1 Curie [Ci].....	58
5-2.1.2 Becquerel [Bq].....	58
5-2.1.3 Gray [Gy].....	58
5-2.1.4 N values.....	59
5-2.1.5 Q values.....	59
5-2.1.6 REM [rem].....	59
5-2.1.7 Sievert [Sv].....	60

5-2.1.8 Rad [rad].....	61
5-2.1.9 SI multipliers	61
5-2.2 <i>Radiation poisoning</i>	61
5-2.2.1 Measuring radiation dosage.....	62
5-2.2.2 Acute (short-term) vs chronic (long-term) effects.....	62
5-2.3 <i>Exposure levels and symptoms</i>	62
5-3 Chelation and detoxification	65
5-3.1 <i>Chelation</i>	65
5-3.2 <i>Detoxification</i>	66
5-3.2.1 Cytochrome P450	66
5-3.2.2 Phase I.....	67
5-3.2.3 Phase II.....	68
5-4 Lipid peroxidation	69
5-5 Detoxifying properties of the human body	69
5-5.1 <i>Glutathione S-transferase</i>	69
6 TOXIC METALS	71
6-1 General considerations	71
6-2 Arsenic (As).....	72
6-2.1 <i>Sources</i>	73
6-2.2 <i>Biochemistry</i>	73
6-2.3 <i>Arsenic and cancer</i>	74
6-2.4 <i>Medical history</i>	74
6-2.5 <i>Clinical Signs and Symptoms</i>	75
6-2.5.1 Acute poisoning	75
6-2.5.2 Chronic poisoning.....	76
6-2.6 <i>Diagnosis</i>	77
6-2.7 <i>Treatment</i>	77
6-2.8 <i>Chelating agents for arsenic</i>	78
6-3 Beryllium (Be).....	78
6-3.1 <i>Sources</i>	78
6-3.2 <i>Biochemistry</i>	79
6-3.3 <i>Toxicity</i>	79
6-3.4 <i>Chelating agents for beryllium</i>	81
6-4 Cadmium (Cd).....	81
6-4.1 <i>Source</i>	81
6-4.2 <i>Biochemistry</i>	82
6-4.3 <i>Toxicity</i>	84
6-4.3.1 Symptoms of acute intoxication	85
6-4.3.2 Symptoms of chronic exposure.....	85
6-4.4 <i>Treatment</i>	86
6-4.5 <i>Laboratory analysis</i>	86
6-4.6 <i>Chelating agents for cadmium</i>	87
6-5 Chromium (Cr)	87
6-5.1 <i>Source</i>	87
6-5.2 <i>Biochemistry</i>	88
6-5.3 <i>Toxicity</i>	89
6-5.4 <i>Symptoms of chromium poisoning</i>	90
6-5.4.1 Acute toxicity.....	90
6-5.4.2 Chronic toxicity	91
6-5.5 <i>Therapeutic considerations</i>	94
6-5.5.1.1 Acute severe intoxication	94
6-5.5.2 Chronic intoxication	95
6-5.6 <i>Therapeutic applications of chromium</i>	95
6-5.7 <i>Chelating agents for chromium</i>	95
6-6 Lead (Pb).....	96
6-6.1 <i>Source</i>	96
6-6.2 <i>Biochemistry</i>	97
6-6.3 <i>Toxicity</i>	98
6-6.4 <i>Clinical signs and symptoms</i>	102
6-6.4.1 Mild symptoms.....	102
6-6.4.2 Symptoms of acute intoxication	102

6-6.5 Laboratory analysis	103
6-6.5.1 Blood.....	103
6-6.5.2 Low level chronic exposure.....	103
6-6.5.3 Interpreting lead analysis results.....	104
6-6.6 Therapeutic considerations	104
6-6.7 Chelating agents for lead	104
6-7 Mercury (Hg).....	105
6-7.1 Sources	105
6-7.2 Ecotoxicology	106
6-7.3 Biochemistry.....	107
6-7.4 Mercury compounds.....	109
6-7.4.1 Amalgam.....	109
6-7.4.2 Methylmercury	110
6-7.4.3 Ethylmercury	110
6-7.4.4 Thiomersal	110
6-7.5 Laboratory analysis	113
6-7.6 Symptoms	113
6-7.6.1 Symptoms of acute toxicity	113
6-7.7 Chronic mercury poisoning	114
6-7.8 Therapeutic considerations	114
6-7.9 Chelating agents for mercury	114
6-8 Nickel (Ni)	114
6-8.1 Sources	115
6-8.2 Biochemistry.....	115
6-8.3 Nickel content in foods	116
6-8.4 Toxicity	116
6-8.4.1 Early symptoms of toxicity	119
6-8.4.2 Acute toxicity symptoms of nickel carbonyl.....	119
6-8.5 Therapeutic considerations	119
6-9 Polonium (Po).....	120
6-9.1 Solid state form	120
6-9.2 Sources	121
6-9.3 Chemistry	122
6-9.4 Applications	122
6-9.5 Toxicity	123
6-9.5.1 Acute effects	123
6-9.5.2 Long term effects	123
6-9.6 Body burden limit.....	123
6-9.7 Precautions	124
6-9.8 Chelating agents	125
7 POTENTIALLY TOXIC METALS	127
7-1 Aluminum (Al)	127
7-1.1 Sources	127
7-1.2 Use	128
7-1.3 Biochemistry.....	129
7-1.4 Absorption and excretion	129
7-1.5 Toxicity	129
7-1.6 Signs and symptoms.....	131
7-1.7 Laboratory analysis	132
7-1.8 Treatment.....	132
7-1.9 Therapeutic considerations in cases of chronic aluminum exposure	132
7-1.10 Chelating agents for aluminum	133
7-2 Antimony (Sb).....	133
7-2.1 Sources	134
7-2.2 Biochemistry.....	134
7-2.3 Dietary intake	134
7-2.4 Toxicity	134
7-2.5 Laboratory analysis	135
7-2.6 Chelating agents for antimony	135
7-3 Barium (Ba).....	135
7-3.1 Available barium salts	136

7-3.2 Sources.....	136
7-3.3 Biochemistry.....	136
7-3.4 Toxicity.....	137
7-3.5 Treatment.....	138
7-3.6 Chelating agents for Barium.....	139
7-4 Bismuth (Bi).....	139
7-4.1 Sources.....	139
7-4.2 Toxicity.....	139
7-4.2.1 Ingestion and symptoms.....	140
7-4.2.2 Chronic intoxication.....	140
7-4.3 Treatment.....	141
7-5 Boron (B).....	141
7-5.1 Sources.....	142
7-5.2 Biochemistry.....	142
7-5.3 Toxicity.....	143
7-5.3.1 Acute toxicity.....	143
7-5.3.2 Chronic toxicity.....	143
7-5.4 Boron deficiency.....	143
7-5.4.1.1 Exceptional needs.....	143
7-5.4.1.2 RDA.....	143
7-5.4.1.3 Therapy range dose.....	144
7-6 Cesium (Cs).....	144
7-6.1 Sources.....	144
7-6.2 Biochemistry.....	144
7-6.3 Toxicity.....	145
7-6.3.1 Radioactive cesium.....	145
7-6.3.2 Non-radioactive cesium compounds.....	145
7-6.4 Medical applications.....	145
7-6.5 Treatment of cesium intoxication.....	146
7-7 (Tri-valent) Chromium (Cr ³⁺).....	146
7-7.1 Dietary sources.....	146
7-7.1.1 Tissue stores.....	147
7-7.2 Normal functions.....	147
7-7.3 Deficiency states.....	147
7-7.4 Toxicity.....	147
7-7.5 Exceptional needs.....	147
7-7.6 Therapy dose range.....	147
7-7.6.1 RDA.....	147
7-8 Cobalt (Co).....	147
7-8.1 Sources.....	148
7-8.2 Biochemistry.....	148
7-8.3 Toxicity.....	149
7-8.3.1 Tissue stores.....	151
7-8.4 Deficiency states.....	151
7-8.5 Exceptional needs.....	152
7-8.6 RDA.....	152
7-8.7 Therapy dose range.....	152
7-9 Copper (Cu).....	153
7-9.1 Sources.....	153
7-9.2 Biochemistry.....	153
7-9.3 Toxicity.....	155
7-9.4 Hereditary disease of copper metabolism.....	155
7-9.4.1 Copper deficiency.....	155
7-9.4.2 Copper excess.....	156
7-9.5 Deficiency states.....	158
7-9.6 Laboratory and testing information.....	159
7-9.7 Exceptional needs.....	159
7-9.8 RDA.....	159
7-9.9 Treatments.....	159
7-9.10 Chelating agents.....	160
7-9.11 Reference range.....	160
7-10 Fluorine (F).....	160

7-10.1 Sources	161
7-10.2 Biochemistry.....	161
7-10.3 Toxicity	161
7-10.4 Acute poisoning.....	162
7-10.5 Chronic poisoning.....	162
7-10.6 Treatment of fluorine intoxication.....	163
7-11 Gadolinium (Gd)	164
7-11.1 Biochemistry.....	165
7-11.2 Sources	165
7-11.3 Toxicity	166
7-11.4 Applications.....	167
7-11.5 Chelating agents for gadolinium.....	168
7-12 Gallium (Ga)	169
7-12.1 Sources	169
7-12.2 Biochemistry.....	170
7-12.3 Toxicity	170
7-12.4 Medical application.....	170
7-12.5 Laboratory analysis	171
7-12.6 Treatment of gallium toxicity	171
7-13 Germanium (Ge).....	171
7-13.1 Sources	171
7-13.2 Biochemistry.....	172
7-13.3 Toxicity	173
7-13.4 Medical application.....	173
7-13.5 Treatment of germanium toxicity.....	174
7-14 Indium (In).....	174
7-14.1 Sources	175
7-14.2 Biochemistry.....	175
7-14.3 Toxicity	175
7-14.4 Medical application.....	175
7-14.5 Chelating agent for indium	176
7-15 Iridium (Ir)	176
7-15.1 Sources	177
7-15.2 Industrial applications.....	177
7-15.3 Medical applications.....	177
7-15.4 Toxicity	177
7-15.5 Chelating agent for iridium	178
7-16 Iron (Fe)	178
7-16.1 Dietary sources	178
7-16.2 Tissue stores	179
7-16.3 Biochemistry.....	179
7-16.3.1 Hemochromatosis	179
7-16.3.1.1 How is hemochromatosis diagnosed?.....	180
7-16.3.1.2 Risk factors	180
7-16.3.1.3 Treatment.....	181
7-16.3.2 Hemosiderosis	181
7-16.4 Toxicity	181
7-16.5 Treatment	183
7-16.6 Challenge testing.....	183
7-16.7 Deficiency states	183
7-16.8 Laboratory Information	184
7-16.9 RDA.....	184
7-16.10 Therapy dose range	184
7-17 Lithium (Li)	184
7-17.1 Sources	184
7-17.2 Biochemistry.....	185
7-17.3 Toxicity	185
7-17.4 Medical application.....	186
7-17.5 Treatment of toxicity.....	187
7-18 Magnesium (Mg).....	188
7-18.1 Sources	188

7-18.2 Tissue stores	189
7-18.3 Biochemistry	189
7-18.4 Toxicity.....	189
7-18.5 Normal range	191
7-18.6 Therapy dose range.....	191
7-18.7 Deficiency states.....	192
7-18.8 Exceptional needs	192
7-18.9 Treatment of hypermagnesemia.....	192
7-18.10 Magnesium Chloride vs Magnesium Sulfate	192
7-19 Manganese (Mn).....	193
7-19.1 Sources.....	194
7-19.2 Biochemistry	195
7-19.3 Interactions	195
7-19.4 Intoxication.....	196
7-19.4.1 Acute intoxication.....	197
7-19.4.2 Chronic intoxication	198
7-19.5 Deficiency states.....	199
7-19.6 Exceptional needs	199
7-19.7 Laboratory findings	199
7-19.7.1 Additional tests	199
7-19.7.2 Treatment of manganese poisoning	200
7-19.8 RDA	200
7-19.9 Therapy dose range.....	200
7-20 Molybdenum (Mo)	200
7-20.1 Sources.....	201
7-20.2 Tissue stores	201
7-20.3 Biochemistry	201
7-20.4 Toxicity.....	201
7-20.5 Treatment of toxicity	202
7-20.6 Deficiency states.....	202
7-20.7 Exceptional needs	202
7-20.8 RDA	202
7-20.9 Therapy dose range.....	202
7-21 Osmium (Os).....	202
7-21.1 Sources.....	203
7-21.2 Biochemistry	203
7-21.3 Symptoms of intoxication.....	204
7-21.4 Laboratory analysis.....	204
7-21.5 Treatment of osmium poisoning	204
7-21.6 Chelating agents.....	205
7-22 Palladium (Pd).....	205
7-22.1 Sources.....	205
7-22.2 Biochemistry	206
7-22.3 Toxicity.....	206
7-22.4 Symptoms of toxicity.....	206
7-22.4.1 Suspected early symptoms of palladium exposure.....	206
7-22.4.2 Suspected symptoms of advanced toxicity	206
7-22.5 Laboratory analysis.....	207
7-22.6 Therapeutic considerations of palladium poisoning	207
7-23 Phosphorus (P)	207
7-23.1 Sources.....	207
7-23.2 Biochemistry	208
7-23.3 Deficiency states.....	208
7-23.4 RDA	208
7-24 Platinum (Pt)	209
7-24.1 Sources.....	209
7-24.2 Biochemistry	209
7-24.3 Toxicity.....	210
7-24.4 Laboratory analysis.....	211
7-24.5 Therapeutic recommendations for platinum poisoning.....	211
7-25 Rubidium (Rb).....	212

7-25.1 Sources	212
7-25.2 Biochemistry.....	213
7-25.3 Medical application.....	213
7-26 Selenium (Se).....	213
7-26.1 Sources	214
7-26.2 Biochemistry.....	214
7-26.3 Toxicity	216
7-26.3.1 Acute toxicity.....	216
7-26.3.2 Chronic toxicity.....	216
7-26.3.3 Treatment of toxicity.....	216
7-26.4 Deficiency states	217
7-26.5 Treatment of selenium poisoning.....	217
7-26.6 Exceptional needs.....	217
7-26.7 RDA.....	217
7-27 Silver (Ag).....	217
7-27.1 Sources	218
7-27.2 Biochemistry.....	218
7-27.3 Toxicity	219
7-27.3.1 Acute toxic effects of silver	220
7-27.4 Symptoms	221
7-27.5 Laboratory analysis	221
7-27.6 Therapeutic considerations of silver poisoning.....	222
7-28 Tellurium (Te).....	222
7-28.1 Sources	222
7-28.2 Biochemistry.....	223
7-28.3 Toxicity	223
7-28.4 Symptoms	223
7-28.5 Treatment of tellurium poisoning.....	224
7-29 Thallium (Tl).....	224
7-29.1 Sources	224
7-29.2 Biochemistry.....	225
7-29.3 Toxicity	225
7-29.4 Laboratory analysis	228
7-29.5 Treatment of thallium poisoning.....	228
7-30 Thorium (Th).....	228
7-30.1 Sources	228
7-30.2 Biochemistry.....	229
7-30.3 Toxicity	229
7-30.4 Symptoms of thorium inhalation.....	229
7-30.5 Laboratory analysis	230
7-30.6 Treatment of thorium poisoning	230
7-31 Tin (Sn).....	230
7-31.1 Sources	230
7-31.2 Biochemistry.....	231
7-31.3 Toxicity	232
7-31.4 Symptoms	233
7-31.5 Treatment of tin poisoning.....	234
7-31.6 Chelating agents for tin	234
7-32 Uranium (U).....	234
7-32.1 Sources	235
7-32.2 Biochemistry.....	236
7-32.3 Toxicity	236
7-32.4 Laboratory analysis	237
7-32.5 Therapeutic considerations of uranium poisoning	238
7-32.5.1 Prevention guidelines.....	238
7-32.5.2 Therapeutic guidelines.....	238
7-32.6 Chelating agents for uranium	240
7-33 Vanadium (V).....	241
7-33.1 Sources	241
7-33.2 Biochemistry.....	242
7-33.3 Clinical uses	243

7-33.4 Toxicity.....	243
7-33.5 Chelating agents for vanadium.....	245
7-34 Zinc (Zn).....	245
7-34.1 Sources.....	246
7-34.2 Biochemistry.....	247
7-34.3 Zinc deficiency.....	249
7-34.4 Zinc and copper.....	250
7-34.5 Zinc and iron.....	250
7-34.6 Zinc and disease.....	251
7-34.7 Intake of zinc.....	252
7-34.8 Toxicity.....	253
7-34.9 Excessive needs.....	253
7-34.10 Treatment of zinc poisoning.....	254
7-34.10.1 Dosage Upper levels (UL) for zinc for infants, children, and adults:.....	255
8 TOXIC METALS AND HOMEOPATHY.....	257
9 CHELATING AGENTS.....	263
9-1 Synthetic chelating agents.....	263
9-1.1 EDTA.....	263
9-1.1.1 Chemical structure.....	263
9-1.1.2 Stability constant.....	264
9-1.1.3 pH.....	264
9-1.1.4 Affinity.....	265
9-1.1.5 Relative concentrations.....	265
9-1.1.6 <i>In vitro</i> versus <i>in vivo</i>	265
9-1.1.7 Pharmacological actions of EDTA.....	266
9-1.1.8 CaNa_2EDTA or MgNa_2EDTA	266
9-1.1.9 EDTA and clotting.....	267
9-1.1.10 The role of platelets.....	268
9-1.1.11 Glycoprotein IIb/IIIa.....	268
9-1.1.12 Prevention of platelet aggregation.....	269
9-1.1.13 Glycoprotein IIb/IIIa inhibitors.....	269
9-1.1.14 Adverse effects of GP IIb/IIIa-inhibitors.....	270
9-1.1.15 EDTA's action on platelets.....	270
9-1.1.16 Pseudothrombocytopenia.....	270
9-1.1.17 Absorption and metabolism of EDTA.....	271
9-1.1.18 EDTA related toxicity and reactions.....	272
9-1.1.18.1 Nephrotoxicity.....	273
9-1.1.18.2 Hypocalcemia.....	274
9-1.1.18.3 Hypoglycemia.....	275
9-1.1.18.4 Hypotension.....	276
9-1.1.18.5 Systemic reactions.....	276
9-1.1.18.6 Fatigue.....	277
9-1.1.18.7 Phlebitis.....	277
9-1.1.18.8 Dermatitis.....	278
9-1.1.18.9 Embolization.....	278
9-1.1.18.10 Seizures.....	278
9-1.1.18.11 Related problems.....	278
9-1.1.18.12 Summary.....	280
9-1.2 Calcium EDTA.....	280
9-1.3 DMSA.....	281
9-1.3.1 Synonym.....	281
9-1.3.2 Formula.....	281
9-1.3.3 Properties.....	281
9-1.3.4 Uses.....	281
9-1.3.5 Side effects.....	282
9-1.3.6 Dosage.....	282
9-1.3.7 Mercury in infants.....	282
9-1.3.8 Supplied as.....	283
9-1.4 DMPS.....	284
9-1.4.1 Synonym.....	284
9-1.4.2 Formula.....	284
9-1.4.3 Properties.....	284
9-1.4.4 Uses.....	284

9-1.4.5 Challenge test	284
9-1.4.6 Side effects	285
9-1.4.7 Dosage	285
9-1.4.8 Supplied as	285
9-1.4.9 Superiorities of <i>i.v.</i> DMPS over oral DMSA	285
9-1.5 DTPA	286
9-1.5.1 Formula	286
9-1.5.2 Pharmacology	286
9-1.5.3 Uses	286
9-1.6 CaNa_3DTPA	287
9-1.6.1 Formula	287
9-1.6.2 Use	287
9-1.6.3 Contraindications	288
9-1.6.4 Warnings and precautions	288
9-1.6.5 Overdosage	288
9-1.6.6 Dosage	289
9-1.6.7 Supplied as	289
9-1.7 ZnNa_3DTPA	289
9-1.7.1 Formula	289
9-1.7.2 Indications	290
9-1.7.3 Contraindications	290
9-1.7.4 Adverse reactions	290
9-1.7.5 Overdosage	291
9-1.7.6 Dosage	291
9-1.7.7 Supplied as	291
9-1.8 Tetrathiomolybdate (TTM)	291
9-1.8.1 Indications	291
9-1.8.2 Research	292
9-1.8.3 Side effects	292
9-1.9 Deferoxamine	293
9-1.9.1 Synonym	293
9-1.9.2 Formula	293
9-1.9.3 Properties	293
9-1.9.4 Uses	293
9-1.9.5 Side effects	293
9-1.9.6 Contraindications	293
9-1.9.7 Dosage	293
9-1.9.8 Supplied as	293
9-1.10 Deferiprone	293
9-1.10.1 Synonyms	293
9-1.10.2 Formula	294
9-1.10.3 Properties	294
9-1.10.4 Use	295
9-1.10.5 Toxicity	295
9-1.10.6 Contraindications	295
9-1.10.7 Side effects	296
9-1.10.8 Dosage	296
9-1.10.9 Supplied as	296
9-1.11 Trientine	296
9-1.11.1 Synonym	296
9-1.11.2 Properties	296
9-1.11.3 Indications	297
9-1.11.4 Contraindications	297
9-1.11.5 Adverse effects	298
9-1.11.6 Supplied as	298
9-1.12 D-penicillamine	298
9-1.12.1 Synonym	298
9-1.12.2 Formula	298
9-1.12.3 Uses	298
9-1.12.4 Contraindications	299
9-1.12.5 Side effects	299
9-1.12.6 Treatment	299
9-1.12.7 Dosage	300
9-1.12.8 Supplied as	300
9-1.13 Prussian blue	300
9-1.13.1 Synonym	300

9-1.13.2 Formula.....	300
9-1.13.3 Uses	300
9-1.13.4 Properties	300
9-1.13.5 Toxicity.....	301
9-1.13.6 Adverse effects	302
9-1.13.7 Dosage	302
9-1.13.8 Supplied as.....	302
9-1.14 British anti-lewisite (BAL).....	302
9-1.14.1 Synonym.....	302
9-1.14.2 Formula.....	302
9-1.14.3 Properties	302
9-1.14.4 Use	303
9-1.14.5 Contraindications	303
9-1.14.6 Supplied as.....	303
9-2 Natural chelating agents	303
9-2.1 Alpha lipoic acid.....	303
9-2.2 Carnosine	303
9-2.2.1 Formula.....	303
9-2.2.2 Properties	303
9-2.2.3 Role of carnosine.....	304
9-2.2.4 Action.....	304
9-2.2.4.1 Antioxidant	304
9-2.2.4.2 Crosslinking prevention.....	305
9-2.2.4.3 Metal chelation	305
9-2.2.4.4 Inhibits glycosylation	305
9-2.2.4.5 Other actions.....	306
9-2.2.5 Dosage	307
9-2.3 Chlorella.....	307
9-2.3.1 Side effects	307
9-2.3.2 Dosage	308
9-2.4 Cilantro	308
9-2.5 HMD.....	309
9-2.6 Lactoferrin.....	309
9-2.6.1 Normal functions.....	309
9-2.6.2 Chelating actions	310
9-2.6.3 Immunity	311
9-2.6.4 Anti-viral action	311
9-2.6.5 Anti-cancer action.....	311
9-2.6.6 Antibacterial properties	311
9-2.6.7 Antioxidant effects	312
9-2.6.8 Precautions.....	312
9-2.6.9 Contraindications	312
9-2.6.10 Dosage	312
9-2.7 N-acetylcysteine (NAC)	313
9-2.8 Vitamin C	313
9-2.9 Zeolite.....	313
9-2.9.1 Biochemistry	313
9-2.9.2 Clinical application.....	314
9-2.9.3 Adverse effects	315
9-2.9.4 Contra-indications.....	315
9-2.9.5 Dosage	315
10 CHALLENGE (PROVOCATION) TESTS FOR TOXIC METALS.....	317
10-1 Toxic metals challenge test.....	317
10-1.1 Base line urine.....	318
10-1.2 Challenged (provoked) urine	318
10-1.3 Protocol for toxic metal challenge test with DMPS.....	319
10-1.4 Chelator – specific reference ranges.....	320
10-1.5 Protocol for toxic metal challenge test with DMSA.....	321
10-1.6 Protocol for toxic metal challenge test with ZnDTPA/DMPS.....	321
10-1.7 Protocol for toxic metal challenge test with DMSA/ZnDTPA/DMPS	322
10-1.8 Protocol for toxic metal challenge test with EDTA/DMSA	323
10-2 Hair elemental analysis	323
11 PROTOCOLS FOR ADMINISTRATION OF CHELATING AGENTS.....	325

11-1 History and physical examination	325
11-2 Synthetic chelating agents	325
11-2.1 EDTA	325
11-2.1.1 Pre-treatment evaluation	325
11-2.1.1.1 Selection of patients – indications	325
11-2.1.1.2 Contraindications and relative contraindications	331
11-2.1.1.3 Patient Informed Consent	334
11-2.1.2 Laboratory testing	335
11-2.1.2.1 Mandatory tests	335
11-2.1.2.2 Additional tests	336
11-2.1.3 Calculations for EDTA chelation – glomerular filtration rate (GFR) therapy	336
11-2.1.4 EDTA chelation treatment procedure	336
11-2.1.4.1 Forms of EDTA	336
11-2.1.4.2 Carrier solutions	337
11-2.1.4.3 Ingredients	338
11-2.1.4.4 Renal function tests	345
11-2.1.4.5 Frequency of treatment	346
11-2.1.5 The golden pre-connection rules	346
11-3 Other synthetic chelation agents	347
11-3.1 DMSA	348
11-3.1.1 Mercury in infants	349
11-3.1.2 Protocol for heavy metal detoxification in children	350
11-3.1.2.1 Selection criteria	350
11-3.1.2.2 Consent	350
11-3.1.2.3 History	351
11-3.1.2.4 Physical examination	351
11-3.1.2.5 DMSA: different regimes	353
11-3.1.2.6 General recommendations	353
11-3.1.2.7 Common side effects	353
11-3.2 DMPS	354
11-3.3 Calcium DTPA	354
11-3.3.1 Summary	356
11-3.4 Zinc DTPA	356
11-3.4.1 Contamination of californium, americum, curium, berkelium or plutonium	356
11-3.4.2 Dosage and administration with contamination of californium, americum, curium, berkelium or plutonium	357
11-3.5 Combined treatment of CaNa_3DTPA and ZnNa_3DTPA	359
11-3.5.1 Guidelines for the combined treatment of CaNa_3DTPA and ZnNa_3DTPA	359
11-3.6 Summary of DTPA administration with contamination of radioactive material	359
11-3.7 Administration as part of chelation program for non-radioactive metals and non-acute intoxication	360
11-3.8 Combining chelating agents DMSA, DMPS and DTPA	360
11-3.9 Tetrathiomolybdate	361
11-3.9.1 Dosage	361
11-3.10 Deferoxamine	361
11-3.11 Deferiprone	361
11-3.11.1 Dosage	361
11-3.11.2 Supplied	362
11-3.12 Trientine	362
11-3.12.1 Dosage	362
11-3.12.2 Adverse effects	363
11-3.12.3 Patient monitoring	363
11-3.13 Prussian blue (PB)	364
11-3.13.1 Dosage and administration	364
11-3.13.2 Therapy guidelines for radiocesium	364
11-3.13.3 Therapy of thallium poisoning	365
11-3.13.4 Summary of administration	365
11-3.14 D-penicillamine	366
11-3.14.1 Dosage	366
11-3.15 BAL	366
11-3.15.1 Dosage	366
11-3.15.2 Side effects	366
11-3.15.3 Supplied	366
11-3.16 Mercury intoxication as a result of amalgam fillings	366
11-4 Natural chelating agents	367

11-4.1 Carnosine	367
11-4.1.1 Use	367
11-4.1.2 Dosage	367
11-4.1.3 Side effects	367
11-4.2 Chlorella	367
11-4.2.1 Dosage	368
11-4.3 Cilantro	368
11-4.3.1 Use	368
11-4.3.2 Dosage	368
11-4.4 Lactoferrin	368
11-4.4.1 Dosage	368
11-4.4.2 Adverse reaction	368
12 LABORATORY ANALYSES.....	369
12-1 Renal function	370
12-1.1 Serum creatinine.....	370
12-1.2 Creatinine in the urin.....	371
12-1.3 β_2 -microglobulin.....	371
12-1.3.1 Indications and limitations	372
12-1.4 Blood urea nitrogen (BUN)	373
12-1.5 Uric acid.....	373
12-2 Cardiovascular risk markers.....	373
12-2.1 Lipids	374
12-2.2 Total cholesterol	374
12-2.3 LDL cholesterol.....	374
12-2.4 HDL cholesterol.....	375
12-2.5 Triglycerides	375
12-3 Lipoproteins.....	375
12-3.1 Lipoprotein(a) or Lp(a).....	376
12-3.2 Apolipoprotein A-1 or ApoA-1	376
12-3.3 Apolipoprotein B or ApoB	376
12-3.4 Ratio of ApoB/ApoA-1.....	377
12-4 Homocysteine	377
12-5 Fibrinogen	378
12-6 D-dimer.....	378
12-6.1 Principles of D-dimer testing.....	378
12-7 Plasma Viscosity (PV).....	380
12-8 Glucose metabolism.....	381
12-9 Glycation	382
12-10 Clotting, aggregation	383
12-10.1 Prothrombin time (PT) and international normalized ratio (INR)	383
12-11 Transferrin, ferritin.....	384
12-11.1 Transferrin	384
12-11.2 Ferritin.....	385
12-12 Porphyrins in urine as biomarker for toxic metals.....	385
12-13 Enzymes	386
12-13.1 Creatine phosphokinase (CPK).....	387
12-13.2 Creatine kinase isoenzym (CK-MB)	387
12-13.3 Troponine 1 (Tn1).....	387
12-13.4 Lactate dehydrogenase (LDH)	388
12-13.5 ASAT, ALAT and γ -GT	388
12-13.6 B-type natriuretic peptide (BNP).....	388
12-13.7 Glutathione S-transferase.....	389
12-14 Cations	390
12-14.1 Potassium and magnesium	390
12-14.2 Calcium.....	391
12-14.3 Other cations	391
12-15 Hormones.....	391
12-15.1 Adrenocortex hormones	391
12-15.2 Male and female hormones	392
12-15.3 PSA.....	392

12-16 C-reactive protein	392
12-16.1 <i>Hs-CRP</i>	393
12-16.1.1 The role of hs-CRP in predicting new cardiovascular events	394
12-17 Microorganisms	394
12-17.1 <i>Chlamydia pneumoniae</i>	394
12-17.2 <i>Helicobacter pylori</i>	395
12-17.3 <i>Cytomegalovirus</i>	395
12-17.4 <i>Nanobacter</i>	395
12-18 Essential and metabolic fatty acids	396
12-19 Vitamin and antioxidant profile	397
12-20 Melatonin	397
12-21 Amino acids	397
12-22 Summary of laboratory testing	398
12-23 Non-invasive testing procedures	399
12-23.1 <i>Stress tolerance test</i>	399
12-23.2 <i>Oculoplethysmography</i>	399
12-23.3 <i>Ultrafast CT scan</i>	400
12-23.4 <i>Arterograph</i>	401
12-24 Invasive testing procedures	403
13 ANTIOXIDANTS	405
13-1 Alpha-lipoic acid (ALA)	405
13-1.1 <i>Structure</i>	405
13-1.2 <i>Function</i>	406
13-1.2.1 Enzyme cofactor	406
13-1.2.2 Antioxidant	406
13-1.2.3 Deficiency	407
13-1.2.4 Disease	407
13-1.2.4.1 Diabetes mellitus	407
13-1.2.4.2 Myocardial infarction	408
13-1.2.4.3 Hepatitis	408
13-1.2.4.4 Cataract	408
13-1.2.4.5 Aging	408
13-1.2.5 Sources	409
13-1.2.5.1 Biosynthesis	409
13-1.2.5.2 Food sources	409
13-1.2.6 Toxicity	409
13-1.2.7 Supplements	409
13-1.2.7.1 Racemic (S) vs. R- α -lipoic acid	410
13-1.2.8 Forms	410
13-1.2.9 Dosage	410
13-1.2.10 Drug interactions	411
13-1.2.11 Possible side effects	411
13-2 DMSO and MSM	411
13-3 Carnosine	413
13-3.1 <i>Formula</i>	413
13-3.2 <i>Function</i>	413
13-3.3 <i>Deficiency</i>	414
13-3.4 <i>Dietary sources</i>	414
13-3.5 <i>Drug interactions</i>	414
13-3.6 <i>Side effects</i>	414
13-3.7 <i>Dosage</i>	414
13-4 Glutathione	415
13-4.1 <i>Function</i>	415
13-4.2 <i>Applications</i>	417
13-4.3 <i>Depletion</i>	417
13-4.3.1 Exogenous oxidative stressors	417
13-4.3.1.1 Liver diseases	417
13-4.3.1.2 Lung	418
13-4.3.1.3 Immunity disorders	418
13-4.3.1.4 Neurodegeneration related to glutathione depletion	419
13-4.3.1.5 Alzheimer's disease (AD)	419
13-4.3.1.6 Atherosclerosis	419

13-4.3.1.7 Pancreatitis	420
13-4.3.1.8 Crohn's disease, gastrointestinal inflammation	420
13-4.3.1.9 Metal intoxication diseases	420
13-4.3.1.10 Aging	420
13-4.4 Repleting glutathione	421
13-4.4.1 Oral vs. <i>i.v.</i> glutathione	421
13-4.4.2 Oral dosing with GSH	421
13-4.4.3 N-acetylcysteine (NAC).....	422
13-4.4.4 L-cysteine	422
13-4.4.5 L-methionine	422
13-4.4.6 SAME	423
13-4.5 Synthetic products	423
13-4.6 Diet.....	423
13-4.7 Toxicity and contraindications	423
13-5 L-Arginine	424
13-5.1 Indications.....	425
13-5.2 Contraindications and adverse reactions	425
13-5.3 Drug interactions.....	426
13-5.4 Dosage and administration	426
13-6 L-aurine	427
13-6.1 Normal functions.....	427
13-6.2 Contraindication.....	427
13-6.3 Body stores.....	427
13-6.4 Exceptional needs	427
13-6.5 Dosage	427
13-7 Melatonin.....	428
13-7.1 Normal functions.....	428
13-7.2 Contraindications	428
13-7.3 Dosage	428
13-7.4 Melatonin and metals.....	428
13-8 N-acetylcysteine (NAC).....	428
13-8.1 Uses.....	429
13-8.2 Dosage	429
13-9 Trimethylglycine (TMG).....	429
13-9.1 Synonym.....	429
13-9.2 Normal functions.....	430
13-9.3 Dosage	430
13-10 Ubiquinone	430
13-10.1 Synonym.....	430
13-10.2 Normal functions.....	430
13-10.3 Exceptional needs	430
13-10.4 Ubiquinol.....	431
13-10.5 Dosage	431
13-11 Vitamin A.....	431
13-11.1 Synonym.....	431
13-11.2 Normal function and chemical structure	431
13-11.3 Antagonist.....	432
13-11.4 Dosage	432
13-11.5 Dietary sources.....	432
13-11.6 Tissue stores	433
13-11.7 Toxicity.....	433
13-11.8 Exceptional needs	433
13-12 Vitamin C.....	433
13-12.1 Synonym.....	433
13-12.2 Antagonists.....	433
13-12.3 Dosage	433
13-12.4 Dietary sources.....	433
13-12.5 Tissue stores	433
13-12.6 Normal functions.....	433
13-12.7 Toxicity.....	434
13-12.8 Exceptional needs	434

13-12.9 Chelation	434
13-13 Vitamin E	434
13-13.1 Biochemistry.....	434
13-13.2 Tocopherols.....	435
13-13.3 Tocotrienols.....	436
13-13.4 Vitamin E deficiency.....	437
13-13.4.1 Abetalipoproteinemia.....	437
13-13.4.2 Heart disease.....	437
13-13.4.3 Parkinson's disease.....	437
13-13.4.4 Alzheimer's disease.....	438
13-13.4.5 Cancer.....	438
13-13.4.6 Cataracts.....	438
13-13.5 Other vitamin E applications.....	438
13-13.6 Deficiency of vitamin E and excessive needs.....	439
13-13.7 Food sources of vitamin E.....	439
13-13.8 Toxicity.....	439
13-13.9 Forms.....	440
13-13.10 Dosage.....	440
14 ADJUNCTIVE HEALTH MEASURES	443
14-1 Dietary guidelines.....	443
14-1.1 Dietary measures.....	443
14-1.1.1 Calcium.....	443
14-1.1.2 Vitamin D.....	444
14-1.1.3 Vitamin B ₁₂	444
14-1.1.4 Vitamin E.....	444
14-1.1.5 Carbohydrates.....	444
14-1.1.6 Meat.....	445
14-1.2 Summarizing.....	445
14-2 Nutritional supplements.....	446
14-2.1 Water-soluble vitamins.....	447
14-2.1.1 Vitamin B1.....	447
14-2.1.1.1 Synonym.....	447
14-2.1.1.2 Antagonists.....	447
14-2.1.1.3 RDA.....	447
14-2.1.1.4 Therapeutic range.....	447
14-2.1.1.5 Dietary sources.....	447
14-2.1.1.6 Tissue stores.....	447
14-2.1.1.7 Function.....	447
14-2.1.1.8 Toxicity.....	447
14-2.1.1.9 Exceptional needs.....	447
14-2.1.2 Vitamin B2.....	447
14-2.1.2.1 Synonym.....	447
14-2.1.2.2 Antagonists.....	447
14-2.1.2.3 RDA.....	448
14-2.1.2.4 Dietary sources.....	448
14-2.1.2.5 Tissue stores.....	448
14-2.1.2.6 Normal functions.....	448
14-2.1.2.7 Toxicity.....	448
14-2.1.2.8 Exceptional needs.....	448
14-2.1.3 Vitamin B3.....	448
14-2.1.3.1 Synonym.....	448
14-2.1.3.2 Antagonists.....	448
14-2.1.3.3 RDA.....	448
14-2.1.3.4 Dietary sources.....	448
14-2.1.3.5 Tissue stores.....	448
14-2.1.3.6 Normal functions.....	448
14-2.1.3.7 Toxicity.....	448
14-2.1.3.8 Exceptional needs.....	449
14-2.1.4 Niacinamide.....	449
14-2.1.4.1 Synonym.....	449
14-2.1.4.2 Antagonists.....	449
14-2.1.4.3 RDA.....	449
14-2.1.4.4 Dietary sources.....	449
14-2.1.4.5 Tissue stores.....	449

14-2.1.4.6 Normal functions	449
14-2.1.4.7 Toxicity	449
14-2.1.4.8 Exceptional needs	449
14-2.1.5 Vitamin B5	449
14-2.1.5.1 Synonym	449
14-2.1.5.2 Antagonist	449
14-2.1.5.3 Dietary sources	449
14-2.1.5.4 Tissue stores	449
14-2.1.5.5 Normal functions	450
14-2.1.5.6 Exceptional needs	450
14-2.1.6 Vitamin B6	450
14-2.1.6.1 Synonym	450
14-2.1.6.2 Antagonists	450
14-2.1.6.3 RDA	450
14-2.1.6.4 Therapy dose range	450
14-2.1.6.5 Dietary sources	450
14-2.1.6.6 Tissue stores	450
14-2.1.6.7 Normal functions	450
14-2.1.6.8 Deficiency states	450
14-2.1.6.9 Toxicity	450
14-2.1.6.10 Exceptional needs	451
14-2.1.7 Vitamin B12	451
14-2.1.7.1 Synonym	451
14-2.1.7.2 Antagonists	451
14-2.1.7.3 Dietary sources	451
14-2.1.7.4 Tissue stores	451
14-2.1.7.5 Normal functions	451
14-2.1.7.6 Exceptional needs	451
14-2.1.7.7 Deficiency states	451
14-2.1.7.8 RDA	452
14-2.1.7.9 Therapy dose range	452
14-2.1.8 Vitamin B15	452
14-2.1.8.1 Synonym	452
14-2.1.8.2 Dietary sources	453
14-2.1.8.3 Tissue stores	453
14-2.1.8.4 Normal function	453
14-2.1.8.5 Toxicity	453
14-2.1.8.6 Exceptional needs	453
14-2.1.8.7 RDA	453
14-2.1.9 Biotin	453
14-2.1.9.1 Synonym	453
14-2.1.9.2 Antagonists	453
14-2.1.9.3 Dietary sources	453
14-2.1.9.4 Tissue stores	453
14-2.1.9.5 Normal functions	453
14-2.1.9.6 Toxicity	453
14-2.1.9.7 Exceptional needs	454
14-2.1.9.8 RDA	454
14-2.1.9.9 Therapy dose range	454
14-2.1.10 Folic acid	454
14-2.1.10.1 Synonym	454
14-2.1.10.2 Exceptional needs	454
14-2.1.10.3 Toxicity	454
14-2.1.10.4 RDA	454
14-2.1.11 Vitamin C	455
14-2.1.12 Bioflavonoids	455
14-2.1.12.1 Synonym	455
14-2.1.12.2 Antagonist	455
14-2.1.12.3 Therapy dose range	455
14-2.1.12.4 Tissue stores	455
14-2.1.12.5 Normal functions	455
14-2.1.12.6 Exceptional needs	455
14-2.1.12.7 RDA	455
14-2.1.13 Choline	455
14-2.1.13.1 Synonym	455
14-2.1.13.2 Antagonists	455
14-2.1.13.3 RDA	455

14-2.1.13.4 Therapy dose range	455
14-2.1.13.5 Dietary sources	455
14-2.1.13.6 Tissue stores	455
14-2.1.13.7 Normal functions	456
14-2.1.13.8 Toxicity	456
14-2.1.13.9 Exceptional needs	456
14-2.1.14 PABA	456
14-2.1.14.1 Synonym	456
14-2.1.14.2 Antagonists	456
14-2.1.14.3 Dietary sources	456
14-2.1.14.4 Tissue stores	456
14-2.1.14.5 Normal functions	456
14-2.1.14.6 Toxicity	456
14-2.1.14.7 Exceptional needs	456
14-2.1.14.8 RDA	456
14-2.2 Fat-soluble vitamins	456
14-2.2.1 Vitamin A	456
14-2.2.2 Vitamin D	457
14-2.2.2.1 Synonym	457
14-2.2.2.2 Antagonists	457
14-2.2.2.3 Dietary sources	457
14-2.2.2.4 Tissue stores	457
14-2.2.2.5 Biochemistry	457
14-2.2.2.6 Toxicity	458
14-2.2.2.7 Exceptional needs	459
14-2.2.2.8 RDA	460
14-2.2.2.9 Therapy dose range	460
14-2.2.3 Vitamin E	460
14-2.2.4 Vitamin K	460
14-2.2.4.1 Synonyms	461
14-2.2.4.2 Chemical structure	461
14-2.2.4.3 Normal functions	462
14-2.2.4.4 Antagonists	463
14-2.2.4.5 Therapy dose range	463
14-2.2.4.6 Supply	464
14-2.2.4.7 Dietary sources	464
14-2.2.4.8 Tissues stores	464
14-2.2.4.9 Toxicity	464
14-2.2.4.10 Exceptional needs	465
14-2.2.4.11 RDA	465
14-2.3 Minerals and trace elements	465
14-2.3.1 Calcium (Ca)	465
14-2.3.1.1 Dietary sources	465
14-2.3.1.2 Tissue stores	465
14-2.3.1.3 Deficiency states	465
14-2.3.1.4 Toxicity	465
14-2.3.1.5 Exceptional needs	465
14-2.3.1.6 Additional information	465
14-2.3.1.7 RDA	466
14-2.3.1.8 Therapy dose range	466
14-2.3.2 Potassium (K)	466
14-2.3.2.1 RDA	466
14-2.3.2.2 Therapy dose range	466
14-2.3.2.3 Dietary sources	466
14-2.3.2.4 Tissue store	466
14-2.3.2.5 Normal function	466
14-2.3.2.6 Deficiencies	466
14-2.3.2.7 Toxicity	466
14-2.3.2.8 Exceptional needs	466
14-2.3.3 Sodium (Na)	466
14-2.3.3.1 RDA	466
14-2.3.3.2 Therapy dose range	467
14-2.3.3.3 Dietary sources	467
14-2.3.3.4 Tissue stores	467
14-2.3.3.5 Normal functions	467
14-2.3.3.6 Deficiency states	467
14-2.4 Lipids and fatty acids	467

14-2.4.1 Sources of fats	468
14-2.4.2 Formulas	468
14-2.4.3 Saturated vs. unsaturated fatty acids	469
14-2.5 <i>Trans and cis fatty acids</i>	469
14-2.6 <i>Essential fatty acids</i>	470
14-2.7 <i>EPA and DHA</i>	471
14-2.7.1 Synonym	471
14-2.7.2 Normal function	471
14-2.7.3 Dosage	471
14-2.7.4 Contraindications	471
14-3 Miscellaneous	471
14-3.1 <i>Alpha-lipoic acid (ALA)</i>	471
14-3.2 <i>DMSO and MSM</i>	472
14-3.3 <i>Glutathione</i>	473
14-3.4 <i>L-arginine</i>	473
14-3.5 <i>L-carnitine, acetyl L-carnitine, L-propionylcarnitine</i>	473
14-3.5.1 L-carnitine	473
14-3.5.1.1 Biochemistry	473
14-3.5.1.2 Body stores	474
14-3.5.1.3 Normal functions of L-carnitine	474
14-3.5.1.4 Carnitine deficiency	474
14-3.5.1.5 Supplementation	475
14-3.5.1.6 Dosage	476
14-3.5.1.7 Toxicity, adverse effects	476
14-3.5.2 Acetyl-L-carnitine (ALC)	476
14-3.5.2.1 Pharmacokinetics	476
14-3.5.2.2 Clinical indications	476
14-3.5.2.3 Dosage	477
14-3.5.2.4 Toxicity	477
14-3.5.3 L-propionylcarnitine (LPC)	477
14-3.5.3.1 Clinical indications	478
14-3.5.3.2 Dosage	478
14-3.5.3.3 Toxicity	478
14-3.5.3.4 Acetyl-L-carnitine vs L-propionylcarnitine vs L-carnitine	478
14-3.5.3.5 Normal function	479
14-3.5.3.6 Body stores	479
14-3.5.3.7 Exceptional needs	479
14-3.6 <i>Lactoferrin</i>	479
14-3.7 <i>L-taurine</i>	479
14-3.8 <i>Melatonin</i>	479
14-3.9 <i>Policosanol</i>	480
14-3.9.1 Function	480
14-3.9.2 Research	480
14-3.9.3 Therapy dose range	480
14-3.10 <i>Resveratrol</i>	480
14-3.10.1 Formula	480
14-3.10.2 Properties	481
14-3.10.3 Role of resveratrol	481
14-3.10.4 Pharmacokinetics	482
14-3.10.5 Therapy dose range	482
14-3.11 <i>Trimethylglycine (TMG)</i>	483
14-3.12 <i>Ubiquinone - Ubiquinol</i>	483
14-4 Adjunctive measures	483
14-4.1 <i>Smoking</i>	483
14-4.2 <i>Exercise</i>	483
14-4.2.1 Types of exercise	484
14-4.3 <i>Stress control</i>	484
15 TOXIC METALS AND SYNDROMES	485
15-1 Atherosclerosis	485
15-1.1 <i>How does atherosclerosis start?</i>	485
15-1.2 <i>Inflammation</i>	486
15-1.2.1 Direct effects of inflammation	486
15-1.2.1.1 Tissue plasminogen activator (tPA)	486

15-1.2.1.2 Prostacyclin PGI ₂ and thromboxane TXA ₂	486
15-1.2.2 Indirect effects of inflammation	487
15-1.3 Growth factors	487
15-1.3.1 Platelet-derived growth factor (PDGF)	487
15-1.3.2 Platelet aggregation	487
15-1.3.3 Transforming growth factors-β (TGFs-β)	487
15-1.3.4 Tumor necrosis factors (TNF)	488
15-1.3.4.1 Tumor necrosis factor-α (TNF-α)	488
15-1.3.4.2 Tumor necrosis factor-β (TNF-β)	488
15-1.3.5 Vascular endothelial growth factor (VEGF)	488
15-1.3.6 VCAM and ICAM	488
15-1.3.7 Interleukins, IL	489
15-1.3.7.1 Interleukin-1 (IL-1)	489
15-1.3.7.2 Interleukin-6 (IL-6)	489
15-1.4 Anti-inflammatory agents	489
15-1.4.1 Transforming growth factor-α (TGF-α)	489
15-1.5 Risk factors	490
15-1.5.1 Asymmetric di-methyl arginine (ADMA)	490
15-1.5.2 Consequences of ADMA	490
15-1.5.3 Nitric oxide (NO)	491
15-1.5.4 eNOS	491
15-1.5.5 Angiogenesis	492
15-1.5.5.1 Sprouting angiogenesis	492
15-1.5.5.2 Intussusceptive angiogenesis	492
15-1.5.5.3 Mediators of angiogenesis	493
15-1.5.5.4 Is plaque angiogenesis pathological or physiological?	493
15-1.5.5.5 The dilemma: physiological versus pathological angiogenesis	494
15-1.5.6 Diabetes	495
15-1.5.7 Fibrinogen	496
15-1.5.8 Hemochromatosis	497
15-1.5.9 Homocysteine	497
15-1.5.9.1 How does homocysteine contribute to atherosclerosis?	497
15-1.5.9.2 Methionine the origin of homocysteine	497
15-1.5.9.3 Methylation and transsulfuration to detoxify homocysteine	498
15-1.5.9.4 Genetic factors in homocysteinemia	499
15-1.5.10 Hypertension	499
15-1.5.11 Inflammation, infectious agents	499
15-1.5.11.1 Chlamydia pneumoniae	500
15-1.5.11.2 Cytomegalovirus (CMV)	500
15-1.5.11.3 Epstein-Barr virus (EBV)	501
15-1.5.11.4 Helicobacter pylori	501
15-1.5.11.5 Parodontosis	501
15-1.5.12 Lipid peroxidation	502
15-1.5.13 Cholesterol oxidation	502
15-1.5.13.1 Low-density lipoprotein (LDL)	502
15-1.5.13.2 Plaque formation	503
15-1.5.14 Lipoprotein(a), Lp(a)	504
15-1.5.15 Can HDL cholesterol become proatherogenic?	505
15-1.6 Antioxidants	505
15-1.7 Laboratory tests for atherosclerosis and risk factors	506
15-1.7.1 High sensitivity-CRP (hs-CRP)	506
15-1.7.2 Fibrinogen	506
15-1.7.3 The Calcium Score	506
15-1.8 Prevention and treatment	507
15-1.8.1 Nutritional supplements	507
15-1.8.1.1 Alpha-lipoic acid (ALA)	507
15-1.8.1.2 Choline	508
15-1.8.1.3 Coenzyme Q10 (ubiquinone,ubiquinol)	508
15-1.8.1.4 Essential fatty acids	508
15-1.8.1.5 L-arginine	509
15-1.8.1.6 L-carnitine	509
15-1.8.1.7 L-taurine	509
15-1.8.1.8 Proanthocyanidins	509
15-1.8.1.9 Picosanol	509
15-1.8.1.10 TMG	510
15-1.8.2 Trace mineral supplements	510

15-1.8.2.1 Chromium (Cr)	510
15-1.8.2.2 Magnesium (Mg)	510
15-1.8.2.3 Selenium (Se)	510
15-1.8.2.4 Zinc (Zn).....	511
15-1.8.3 Vitamins	511
15-1.8.3.1 Vitamin C	511
15-1.8.3.2 Vitamin E.....	511
15-1.8.3.3 Vitamin K ₂ (Menaquinone)	511
15-1.8.4 Herbal supplements, examples.....	511
15-1.8.4.1 Bromelain.....	511
15-1.8.4.2 Curcumin.....	512
15-1.8.4.3 Garlic.....	512
15-1.8.4.4 Ginger (Zingiber officinale).....	512
15-1.8.4.5 Ginkgo biloba	512
15-1.8.4.6 Green tea extract	513
15-1.8.4.7 Gugulipid.....	513
15-1.8.4.8 Hawthorn berry.....	513
15-1.9 Treatment of controllable risk factors	513
15-1.9.1 <i>Chlamydia pneumoniae</i>	513
15-1.9.2 Diabetes.....	514
15-1.9.2.1 Sulfonylureas and CHD.....	514
15-1.9.2.2 Alpha-lipoic acid	514
15-1.9.2.3 Carnosine.....	514
15-1.9.2.4 Chromium	514
15-1.9.2.5 Fiber.....	514
15-1.9.2.6 Zinc	514
15-1.9.3 Exercise.....	514
15-1.9.4 Hyperhomocysteinemia	515
15-1.9.4.1 Homocysteine lowering nutrients	515
15-1.9.4.2 Creatine	515
15-1.9.4.3 Folic acid.....	515
15-1.9.4.4 Niacin	515
15-1.9.4.5 Niacinamide	515
15-1.9.4.6 Inositol hexaniacinate.....	516
15-1.9.4.7 Vitamin B ₆	516
15-1.9.4.8 Trimethylglycine (TMG), betaine	516
15-1.9.5 Periodontitis.....	517
15-1.9.6 Smoking.....	517
15-1.9.7 Magnesium EDTA <i>i.v.</i> chelation therapy.....	517
15-1.10 Conventional medical therapy	517
15-1.10.1 Drug treatments medication.....	517
15-1.10.1.1 Aspirin	517
15-1.10.1.2 Platelet aggregation inhibitors.....	518
15-1.10.1.3 Magnesium EDTA.....	518
15-1.10.1.4 Statin drugs	518
15-1.10.1.5 Cholesterol - independent or "pleiotropic" effects of statins	519
15-1.11 Invasive procedures.....	521
15-1.11.1 Coronary artery bypass.....	521
15-1.11.2 Angioplasty	521
15-1.11.3 Stenting.....	522
15-1.11.4 Coronary navigation.....	523
15-1.11.5 Intra-coronary radiation, brachytherapy	524
15-1.11.6 Atherectomy.....	524
15-2 Alzheimer's disease	527
15-3 Autism	530
15-4 Multiple sclerosis (MS).....	533
15-4.1 Causes.....	533
15-4.2 Methylation and multiple sclerosis.....	534
15-4.3 A comprehensive program for MS.....	534
15-5 Wilson's disease (hepato-lenticular degeneration)	535
15-5.1 Pathology.....	535
15-5.2 Diagnosis.....	536
15-5.3 How is Wilson's disease inherited?	537
15-5.4 Signs and symptoms	538
15-5.5 Treatment	539

16 APPENDIX 1	541
16-1 Example of an informed consent for Mg-EDTA Chelation Therapy	541
17 APPENDIX 2	543
17-1 Glomerular filtration rate (GFR) calculation for EDTA chelation therapy	543
17-1.1 Calculating EDTA dosages according Cockcroft Gault by Hasnain Patel MD	543
17-1.2 Carrier solutions	546
17-1.2.1 Lactated ringers solution	546
17-1.2.2 Saline (0,9% or 0,65%) or glucose 5%	547
17-1.2.3 Ingredients	547
17-1.3 Standard ingredients of a MgEDTA chelation infusion	548
17-2 Dosage of EDTA	548
17-3 Infusion rate	549
17-4 EDTA equivalents in ml	549
17-5 Osmolarity of various ingredients in milli-Osmoles per ml [mOs/ml]	550
17-6 Other possible ingredients of an EDTA chelation therapy infusion	551
17-7 Calculation of magnesium in MgEDTA	552
17-8 Other adjunctives	553
17-9 Other useful i.v. therapies	553
17-10 High vitamin C protocol	553
17-11 Example of a standard oral vitamin and mineral program during EDTA chelation therapy	554
17-12 Example of variables - based on test results and clinical view	554
17-13 Affinity of various chelating agents for toxic metals	555
18 APPENDIX 3	557
18-1 Medical components unit conversion factors	557
19 APPENDIX 4	561
19-1 The International Board of Clinical Metal Toxicology, IBCMT	561
19-1.1 Purpose	561
19-1.2 Workshops	561
19-1.2.1 Requirements for IBCMT workshop approval	562
19-1.3 Examinations	562
20 REFERENCES	565
20-1 Alpha lipoic acid	565
20-2 Aluminum	566
20-3 Alzheimer's disease	566
20-4 Arsenic	567
20-5 Atherosclerosis	567
20-6 Autism	567
20-7 BAL	568
20-8 Biochemistry	568
20-9 Bismuth	569
20-10 Brain Natriuretic Peptide	569
20-11 Cadmium	569
20-12 Calcium EDTA	569
20-13 Carnitine	570
20-14 Carnosine	572
20-15 Chelation, general	572
20-16 Chemistry refresher	574
20-17 Chlorella	574
20-18 Cilantro	574
20-19 Chromium	575
20-20 Copper	575
20-21 Curcumin	575
20-22 Deferiprone	577
20-23 Desferrioxamine	578
20-24 DMPS	578

20-25 DMSA.....	578
20-26 D-penicillamine.....	578
20-27 EDTA.....	578
20-27.1 EDTA, arrhythmia.....	582
20-27.2 EDTA, atherosclerosis.....	582
20-27.3 EDTA, calcium.....	585
20-27.4 EDTA, cancer.....	586
20-27.5 EDTA, digitalis.....	586
20-27.6 EDTA, granulomatosis.....	587
20-27.7 EDTA, kidneys.....	587
20-27.8 EDTA, multiple sclerosis.....	588
20-27.9 EDTA, pharmacological action.....	588
20-27.10 EDTA, platelets.....	589
20-27.11 EDTA, politics.....	589
20-27.12 EDTA, porphyria.....	590
20-27.13 EDTA, PTH.....	590
20-27.14 EDTA, rheumatoid disease.....	591
20-27.15 EDTA, sarcoidosis.....	591
20-27.16 EDTA, scleroderma.....	591
20-27.17 EDTA, toxicity.....	591
20-27.18 EDTA, vitamin C.....	592
20-28 Free radicals.....	592
20-29 Gadolinium.....	593
20-30 Glutathione.....	593
20-31 Hair analysis.....	595
20-32 History of chelation.....	595
20-33 Iron.....	596
20-34 Laboratory.....	596
20-35 Lactoferrin.....	596
20-36 L-arginine.....	597
20-37 Lead.....	598
20-38 Homeopathy and chelation.....	599
20-39 Mercury.....	601
20-40 Miscellaneous.....	601
20-41 Multiple sclerosis.....	603
20-42 N-acetylcysteine.....	603
20-43 Nickel.....	604
20-44 Nutrition.....	604
20-45 Osmium.....	605
20-46 Parkinson's disease.....	605
20-47 Porphyrinuria as biomarker.....	605
20-48 Resveratrol.....	605
20-49 Selenium.....	606
20-50 Polonium.....	606
20-51 Tetrathiomolybdate.....	607
20-52 Thalassemia major.....	607
20-53 Tobacco smoke.....	607
20-54 Trientine.....	607
20-55 Ubiquinol.....	608
20-56 Ubiquinone.....	608
20-57 Vitamin D.....	609
20-58 Vitamin E.....	609
20-59 Vitamin K.....	611
20-60 Zinc.....	611